Biomedical research (or experimental medicine), in general simply known as medical research which is the basic research, applied research, or translational research conducted to aid and support the development body of knowledge in the field of medicine. Medical research can be divided into two general categories: the evaluation of new treatments for both safety and efficacy in what are termed clinical trials, and all other research that contributes to the development of new treatments. The latter is termed preclinical research if its goal is specifically to elaborate knowledge for the development of new therapeutic strategies. A new paradigm to biomedical research is being termed translational research, which focuses on iterative feedback loops between the basic and clinical research domains to accelerate knowledge translation from the bedside to the bench, and back again. Medical research may involve doing research into public health, biochemistry, clinical research, microbiology, physiology, oncology, surgery and research into many other non-communicable diseases such as diabetes and cardiovascular diseases.
The increased longevity of humans over the past century can be significantly attributed to advances resulting from medical research. Among the major benefits of medical research have been vaccines for measles and polio, insulin treatment for diabetes, classes of antibiotics for treating a host of maladies, medication for high blood pressure, improved treatments for AIDS, statins and other treatments for atherosclerosis, new surgical techniques such as microsurgery, and increasingly successful treatments for cancer. New, beneficial tests and treatments are expected as a result of the Human Genome Project. Many challenges remain, however, including the appearance of antibiotic resistance and the obesity epidemic.
Most of the research in the field is pursued by biomedical scientists, however significant contributions are made by other biologists, as well as chemists and physicists. Medical research, done on humans, has to strictly follow the medical ethics as sanctioned in the Declaration of Helsinki and elsewhere. In all cases, the research ethics has to be respected.
- 1 Preclinical research
- 2 Clinical trials
- 3 Funding
- 4 Regulations and guidelines
- 5 Flaws and vulnerabilities
- 6 Fields of research
- 7 See also
- 8 References
- 9 External links
Preclinical research is a stage of research that begins before clinical trials (testing in humans) can begin, and during which important feasibility, iterative testing and drug safety data is collected and analyzed.
The main goals of pre-clinical studies are to profile and determine a product's ultimate safety on humans. Products may include new or iterated or like-kind medical devices, drugs, gene therapy solutions, etc.
A clinical trial is a comparison test of a medication or other medical treatment, versus a placebo, other medications and devices, or the standard medical treatment for a patient's condition. Clinical trials can vary greatly in size: from a single researcher in one hospital or clinic to an international multicenter trial with several hundred participating researchers on several continents. The number of patients tested can range from as few as a dozen to several thousands.
Research funding in many countries derives from research bodies and private organizations which distribute money for equipment and salaries. In the United Kingdom, funding bodies such as the Medical Research Council derive their assets from UK tax payers, and distribute this to institutions in a competitive manner. The Wellcome Trust is the UK's largest non-governmental source of funds for biomedical research and provides over £600 million per year in grants to scientists and funds for research centres.
In the United States, the most recent data from 2003 suggest that about 94 billion dollars were provided for biomedical research in the United States. The National Institutes of Health and pharmaceutical companies collectively contribute 26.4 billion dollars and 27.0 billion dollars, respectively, which constitute 28% and 29% of the total, respectively. Other significant contributors include biotechnology companies (17.9 billion dollars, 19% of total), medical device companies (9.2 billion dollars, 10% of total), other federal sources, and state and local governments. Foundations and charities, led by the Bill and Melinda Gates Foundation, contributed about 3% of the funding.
In Australia, in 2000/01 (the most recent data available), about $1.7B was spent on biomedical research, with just under half ($800M, 47%) sourced from the Commonwealth government (all sources). About $540M came from business investments/funding and a further $220M from private or not-for-profit organisations (totalling 44%). The balance was from state and local governments. Since then there has been a significant in government funding through the National Health and Medical Research Council (NHMRC), whose expenditure on research was nearly A$700 million in 2008-09.
The enactment of orphan drug legislation in some countries has increased funding available to develop drugs meant to treat rare conditions, resulting in breakthroughs that previously were uneconomical to pursue.
Government-Funded Biomedical Research
Since the establishment of the National Institutes of Health (NIH) in the mid1940’s, the main source of U.S. Federal support of biomedical research, investment priorities and levels of funding have fluctuated. From 1995 to 2010, NIH support of biomedical research increased from 11 billion to 27 billion  Despite the jump in federal spending, advancements measured by citations to publications and the number of drugs passed by the FDA along with other measures of scientific achievement remained stagnant over the same time span. Financial projections indicate federal spending will remain constant in the near future.
US Federal Funding Trends
The National Institutes of Health (NIH) is the agency that is responsible for management of the lions-share of federal funding of biomedical research. Over the past century there were two notable periods of NIH support. From 1995 to 1996 funding increased from $8.877 billion to $9.366 billion, years which represented the start of what is considered the “doubling period” of rapid NIH support. The second notable period started in 1997 and ended in 2010, a period where the NIH moved to organize research spending for engagement with the scientific community. In 1997 Applications were added and in 2000 Awards had been added. These changes were coupled with increasing support; funding rose from $13 billion in 1997 to approximately $27 billion in 2010. The American Recovery and Reinvestment Act of 2009 should also be noted in this history of NIH funding of biomedical research as it committed further funds in the midst of the great recession.
Estimating Long-Term Economic Returns of NIH Funding on Output in the Biosciences published in August, 2012 describes the latest trends of NIH organization. In recent years, the NIH has started to publish medical research trials Success Rates per dollar spent, an initiative which illustrates that research efficiency is viewed as a significant issue both by the public and policy makers.
Privately (Industry) funded biomedical research
Since 1980 the share of biomedical research funding from industry sources has grown from 32% to 62%, which has resulted in the development of numerous life-saving medical advances. The relationship between industry and government funded research in the US has seen great movement over the years. The 1980 Bayh Doyle Act was passed by Congress to foster a more constructive relationship between the collaboration of government and industry funded biomedical research. The Bayh Doyle Act gave private corporations the option of applying for government funded grants for biomedical research which in turn allowed the private corporations to license the technology. Both government and industry research funding increased rapidly from between the years of 1994-2003; industry saw a compound average annual growth rate of 8.1% a year and slowed only slightly to a compound average annual growth rate of 5.8% from 2003-2008.
The funding from industry for pharmaceutical research, a large part of all industry funded research, has slowed since 1994 due to multiple perceptions, lower approval rates from the FDA, increased costs with clinical trials due to more stringent regulation and longer anticipation for return on investment. A 2004 study showed that to bring a drug to market, drug development requires an average of 12–15 years and can reach costs up to $1.7 billion.
The influence of funding on research and the management of conflicts of interests
Conflict of Interest “a set of conditions in which professional judgment concerning a primary interest (such as a patients welfare or the validity of research) tends to be unduly influenced by a secondary interest (such as financial gain).”
In the early 1900’s private companies such as the Carbolic Smoke Ball Company, Mrs. Winlow’s Soothing Syrup among other snake medicine remedies were solicited around the world and were the cause of many deaths due to misinformation. Information was not readily available to consumers nor was it required of the pharmaceutical producers to inform their customers of the ingredients that they were consuming. Samuel Hopkins Adams was an investigator to uncover the wide corruption and falsehoods that existed within the American pharmaceutical industry. He is quoted saying:“Gullible America will spend this year some seventy-five millions of dollars in the purchase of patent medicines. In consideration of this sum it will swallow huge quantities of alcohol, an appalling amount of opiates and narcotics, a wide assortment of varied drugs ranging from powerful and dangerous heart depressants to insidious liver stimulants; and far in excess of all other ingredients, undiluted fraud.”
Regulation on industry funded biomedical research has seen great changes since Samuel Hopkins Adams declaration. In 1906 congress passed the Pure Food and Drugs Act of 1906. In 1912 Congress passed the Shirley Amendment to prohibit the wide dissemination of false information on pharmaceuticals. The Food and Drug Administration was formally created in 1930 under the McNarey Mapes Amendment to oversee the regulation of Food and Drugs in the United States. In 1962 the Kefauver-Harris Amendments to the Food, Drug and Cosmetics Act made it so that before a drug was marketed in the United States the FDA must first approve that the drug was safe. The Kefauver-Harris amendments also mandated that more stringent clinical trials must be performed before a drug is brought to the market. The Kefauver-Harris amendments were met with opposition from industry due to the requirement of lengthier clinical trial periods that would lessen the period of time in which the investor is able to see return on their money. In the pharmaceutical industry patents are typically granted for a 20 year period of time and most patent applications are submitted during the early stages of the product development. According to Ariel Katz on average after a patent application is submitted it takes an additional 8 years before the FDA approves a drug for marketing. As such this would leave a company with only 12 years to market the drug to see a return on their investments. After a sharp decline of new drugs entering the US market following the 1962 Kefauver-Harris amendments economist Sam Petlzman concluded that cost of loss of innovation was greater than the savings recognized by consumers no longer purchasing ineffective drugs. In 1984 the Hatch-Waxman Act or the Drug Price Competition and Patent Term Restoration Act of 1984 was passed by congress. The Hatch-Waxman Act was passed with the idea that giving brand manufacturers the ability to extend their patent by an additional 5 years would create greater incentives for innovation and private sector funding for investment.
The relationship that exists with industry funded biomedical research is that of which industry is the financier for academic institutions which in turn employ scientific investigators to conduct research. A fear that exists wherein a project is funded by industry is that firms might negate informing the public of negative effects to better promote their product. A list of studies show that public fear of the conflicts of interest that exist when biomedical research is funded by industry can be considered valid after a 2003 publication of “Scope and Impact of Financial Conflicts of Interest in Biomedical Research” in The Journal of American Association of Medicine. This publication included 37 different studies that met specific criteria to determine whether or not an academic institution or scientific investigator funded by industry had engaged in behavior that could be deduced to be a conflict of interest in the field of biomedical research. Survey results from one study concluded that 43% of scientific investigators employed by a participating academic institution had received research related gifts and discretionary funds from industry sponsors. Another participating institution surveyed showed that 7.6% of investigators were financially tied to research sponsors, including paid speaking engagements (34%), consulting arrangements (33%), advisory board positions (32%) and equity (14%). A 1994 study concluded that 58% out of 210 life science companies indicated that investigators were required to withhold information pertaining to their research as to extend the life of the interested companies’ patents. Rules and regulations regarding conflict of interest disclosures are being studied by experts in the biomedical research field to eliminate conflicts of interest that could possibly affect the outcomes of biomedical research.
The first known medical trial was conducted in 605 BC when Babylonian king Nebuchadnezzar ordered children of royal blood to eat only red meat and wine for three years, while another group of children ate only bread and water. The experiment was intended to determine the best nutritional regimen to keep the military troops in peak physical condition and at the experiment endpoint the trial accomplished its prerogative: the children who ate meat and wine were noticeably healthier. Scientific curiosity to understand health outcomes from varying treatments has been present for centuries, but it was not until the mid-19th century when an organizational platform was created to support and regulate this curiosity. In 1945, Vannevar Bush said that biomedical scientific research was “the pacemaker of technological progress” an idea which contributed to initiative to found the National Institutes of Health (NIH) in 1948, a historical benchmark that marked the beginning of a near century substantial investment in biomedical research. The NIH provides more financial support for medical research that any other agency in the world to date and claims responsibility for numerous innovations that have improved global health. The historical funding of biomedical research has undergone many changes over the past century. Innovations such as the polio vaccine, antibiotics and antipsychotic agents, developed in the early years of the NIH lead to social and political support of the agency. Political initiatives in the early 1990s lead to a doubling of NIH funding, spurring an era of great scientific progress. There have been dramatic changes in the era since the turn of the 21st century to date; roughly around the start of the century, the cost of trials dramatically increased while the rate scientific discoveries did not kept pace.
Biomedical research spending increased substantially faster than GDP growth over the past decade in the US, between the years of 2003 and 2007 spending increased 14% per year, while GDP growth increased 1% over the same period (both measures adjusted for inflation). Industry, not-for-profit entities, state and federal funding spending combined accounted for an increase in funding from $75.5 billion in 2003 to $101.1 billion in 2007. Due to the immediacy of federal financing priorities and stagnant corporate spending during the recession, biomedical research spending decreased 2% in real terms in 2008. Despite an overall increase of investment in biomedical research, there has been stagnant, and in some areas a marked decline in the number of drug and device approvals over the same time period.
Today, industry sponsored research accounts for 58% of expenditures, NIH for 27% of expenditures, state governments for 5% of expenditures, non NIH-federal sources for 5% of expenditures and not-for-profit entities accounted for 4% of support. Federally funded biomedical research expenditures increased nominally, 0.7% (adjusted for inflation), from 2003 to 2007. Previous reports showed a stark contrast in federal investment, from 1994 to 2003, federal funding increased 100% (adjusted for inflation).
The NIH manages the lions-share, over 85%, of federal biomedical research expenditures. NIH support for biomedical research decreased from $31.8 billion in 2003, to $29.0 billion in 2007, a 25% decline (in real terms adjusted for inflation), while non-NIH federal funding allowed for the maintenance of government financial support levels through the era (the 0.7% four-year increase). Spending from industry-initiated research increased 25% (adjusted for inflation) over the same time period of time, from 2003-2007, an increase from $40 billion in 2003, to $58.6 billion in 2007. Industry sourced expenditures from 1994-2003 showed industry sponsored research funding increased 8.1%, a stark contrast to 25% increase in recent years.
Of industry sponsored research, pharmaceutical firm spending was the greatest contributor from all industry sponsored biomedical research spending, but only increased 15% (adjusted for inflation) from 2003 to 2007, while device and biotechnology firms accounted for the majority of the spending. The stock performance, a measure that can be an indication of future firm growth or technological direction, has substantially increased for both predominantly medical device and biotechnology producers. Contributing factors to this growth are thought to be less rigorous FDA approval requirements for devices as opposed to drugs, lower cost of trials, lower pricing and profitability of products and predictable influence of new technology due to a limited number of competitors. Another visible shift during the era was a shift in focus to late stage research trials; formerly dispersed, since 1994 an increasingly large portion of industry-sponsored research was late phase trials rather than early-experimental phases now accounting for the majority of industry sponsored research. This shift is attributable to a lower risk investment and a shorter development to market schedule. The low risk preference is also reflected in the trend of large pharmaceutical firms acquiring smaller companies that hold patents to newly developed drug or device discoveries which have not yet passed federal regulation (large companies are mitigating their risk by purchasing technology created by smaller companies in early-phase high-risk studies). Medical research support from Universities increased from $22 billion in 2003 to $27.7 billion in 2007, a 7.8% increase (adjusted for inflation). In 2007 the most heavily funded institutions received 20% of HIN medical research funding, and the top 50 institutions received 58% of NIH medical research funding, the percent of funding allocated to the largest institutions is a trend which has increased only slightly over data from 1994. Relative to federal and private funding, health policy and service research accounted for a nominal amount of sponsored research; health policy and service research was funded $1.8 billion in 2003, which increased to $2.2 billion in 2008.
Stagnant rates of investment from the US government over the past decade, may be in part attributable to challenges that plague the field. To date only two-thirds of published drug trial finding have results that can be re-produced, which raises concerns from a US regulatory standpoint where great investment has been made in research ethics and standards, yet trial results remain inconsistent. Federal agencies have called upon greater regulation to address these problems; a spokesman from the National Institute of Neurological Disorders and Stroke, an agency of the NIH, stated that there is “widespread poor reporting of experimental design in articles and grant applications, that animal research should follow a core set of research parameters, and that a concerted effort by all stakeholders is needed to disseminate best reporting practices and put them into practice”.
Two laws which are both still in effect, one passed in 2006 and the other in 2010, were instrumental in defining funding reporting standards for biomedical research, and defining for the first time reporting regulations that were previously not required. The 2006 Federal Funding Accountability and Transparency Act mandates that all entities receiving over $25,000 in federal funds must report annual spending reports, including disclosure of executive salaries. The 2010 amendment to the act mandates that progress reports be submitted along with financial reporting. Data from the federal mandate is managed and made publicly available on usaspening.gov. Aside from the main source, usaspending.gov, other reporting mechanisms exist: Data specifically on biomedical research funding from federal sources is made publicly available by the National Health Expenditure Accounts (NHEA), data on health services research, approximately 0.1% of federal funding on biomedical research, is available through the Coalition of Health Services Research, the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Centers for Medicare & Medicaid Services, and the Veterans Health Administration.
Currently there are not any funding reporting requirements for industry sponsored research, but there has been voluntary movement toward this goal. In 2014, major pharmaceutical stakeholders such as Roche and Johnson and Johnson have made financial information publicly available and Pharmaceutical Research and Manufacturers of America (PhRMA), the most prominent professional association for biomedical research companies, has recently begun to provide limited public funding reports.
Regulations and guidelines
Medical research is very highly regulated. National regulatory authorities are appointed in almost every country worldwide to oversee and monitor medical research, such as for the development and distribution of new drugs. In the USA the Food and Drug Administration oversees new drug development, in Europe the European Medicines Agency (see also EudraLex), and in Japan the Ministry of Health, Labour and Welfare (Japan). The World Medical Association develops the ethical standards for the medical profession, involved in medical research. The most fundamental of them is the Declaration of Helsinki. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) works on the creation of rules and guidelines for the development of new medication, such as the guidelines for Good Clinical Practice (GCP). All ideas of regulation are based on a country's ethical standards code. This is why treatment of a particular disease in one country may not be allowed, but is in another.
Flaws and vulnerabilities
A major flaw and vulnerability in biomedical research appears to be the hypercompetition for the resources and positions that are required to conduct science. The competition seems to suppress the creativity, cooperation, risk-taking, and original thinking required to make fundamental discoveries. Other consequences of today's highly pressured environment for research appear to be a substantial number of research publications whose results cannot be replicated, and perverse incentives in research funding that encourage grantee institutions to grow without making sufficient investments in their own faculty and facilities.
Fields of research
Fields of biomedical research include:
- Animal testing
- Biomedical informatics
- Biomedical scientist
- Biomedical technology
- Cancer research
- Human experimentation
- Medical research scientist
- Medical Scientist Training Program
- Pharmaceutical company
- Preclinical imaging
- Title 21 of the Code of Federal Regulations (USA)
- Translational Research
- Rapid Research Education
- Chakma, J.; Sun, G. H.; Steinberg, J. D.; Sammut, S. M.; Jagsi, R. (2014). "Asia's Ascent — Global Trends in Biomedical R&D Expenditures". New England Journal of Medicine 370 (1): 3–6. doi:10.1056/NEJMp1311068. PMID 24382062.
- "Henry Wellcome: from backwoods boy to medicine man". The Guardian. 9 January 2011. Retrieved 12 June 2011.
- Moses H, Dorsey E, Matheson D, Thier S (2005). "Financial anatomy of biomedical research.". JAMA 294 (11): 1333–42. doi:10.1001/jama.294.11.1333. PMID 16174691.
- Investment Review of Health and Medical Research (Grant Review) (2004). Sustaining the Virtuous Cycle For a Healthy, Competitive Australia. Department of Health and Ageing.
- NHMRC Annual Report 2008-09, 2009
- . National Institutes of Health http://www.nih.gov. Retrieved Retrieved 2014. Missing or empty
- Frist, William H. (3 April 2002). "Federal Funding for Biomedical Research". JAMA 287 (13): 1722. doi:10.1001/jama.287.13.1722.
- Steinbrook, Robert (9 April 2009). "The NIH Stimulus — The Recovery Act and Biomedical Research". New England Journal of Medicine 360 (15): 1479–1481. doi:10.1056/NEJMp0901819.
- Bekelman, Justin E.; Li, Yan; Gross, Cary P. (22 January 2003). "Scope and Impact of Financial Conflicts of Interest in Biomedical Research". JAMA 289 (4): 454. doi:10.1001/jama.289.4.454.
- Alicia Loffler; Scott Stern. "The Future of the Biomedical Industry in an Era of Globalization". Retrieved 2014.
- Dorsey, E. Ray (13 January 2010). "Funding of US Biomedical Research, 2003-2008". JAMA 303 (2): 137–143. doi:10.1001/jama.2009.1987.
- Thompson, Dennis (August 19, 1993). "Understanding Financial Conflicts of Interest". The New England Journal of Medicine. 329:573-576.
- Katz, Ariel. "Pharmaceutical Lemons: Innovation and Regulation in the Drug Industry". Retrieved 2014.
- "Significant Dates in U.S. Food and Drug Law History". Retrieved 2014.
- Martha Rumore (August 15, 2009). "The Hatch-Waxman Act--25 Years Later: Keeping the Pharmaceutical Scales Balanced". www.pharmacytimes.com. Retrieved 2014.
- Collier, R. (6 January 2009). "Legumes, lemons and streptomycin: A short history of the clinical trial". Canadian Medical Association Journal 180 (1): 23–24. doi:10.1503/cmaj.081879.
- Collier, R. (6 January 2009). "Legumes, lemons and streptomycin: A short history of the clinical trial". Canadian Medical Association Journal 180 (1): 23–24. doi:10.1503/cmaj.081879.
- "Basic Research: the pacemaker of progress". scienceguide.nl/. Retrieved 2014.
- Judith Johson (December 23, 2013). "Brief History of NIH Funding: Fact Sheet". Retrieved 2014.
- Dorsey, E. Ray (13 January 2010). "Funding of US Biomedical Research, 2003-2008". JAMA 303 (2): 137. doi:10.1001/jama.2009.1987.
- "Improving Reproducibility and Transparency in Biomedical Research". drugabuse.gov. Retrieved 2014.
- "Requirements for Federal Funding Accountability and Transparency Act Implementation". hrsa.gov. Retrieved 2014.
- "Industry and Non-Profits Join Forces to Accelerate Discovery of Therapies for Alzheimer's, Diabetes, RA, and Lupus". policymed.com. Retrieved 2014.
- Bruce Albertsa, Marc W. Kirschnerb, Shirley Tilghmanc, and Harold Varmus, Rescuing US biomedical research from its systemic flaws, Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 16, April 2014
- Kolata, Gina (April 23, 2009). "Advances Elusive in the Drive to Cure Cancer". The New York Times. Retrieved 2009-12-29.
- Kolata, Gina (June 27, 2009). "Grant System Leads Cancer Researchers to Play It Safe". The New York Times. Retrieved 2009-12-29.
- Leaf, Clifton (2004-03-22). "Why We're Losing The War On Cancer". Fortune Magazine (CNN Money).
- Abhaya Indrayan (2004). "Elements of medical research.". Indian J Med Res 119 (3): 93–100. PMID 15115159.
- Highleyman L (2006). "A guide to clinical trials. Part II: interpreting medical research.". BETA 18 (2): 41–7. PMID 16610119.Full text
- Beyleveld D & Pattinson S D (2006). "Medical Research into Emergency Treatment: Regulatory Tensions in England and Wales.". Web JCLI 5. full text
- Andorno R (2010). Regulatory discrepancies between the Council of Europe and the EU regarding biomedical research. In: Andre den Exter (ed.), Human Rights and Biomedicine. Antwerp: Maklu Press, pages 117-133.full text
|Wikimedia Commons has media related to Medical research.|
- Johns Hopkins Research Ethics
- SciClyc An Open-access database to shared antibodies, cell cultures, and documents for biomedical research.
- European Clinical Research Infrastructures Network
- MedRACS Clinical Research Blog
- Biomedical Research